Researchers identified a mechanism by which KRAS mutations promote tumor cell survival by degrading the CCDC6 tumor suppressor, leading to increased xCT expression and protection from oxidative stress. (Apoptosis)
Oncogenic KRAS drives xCT upregulation and ferroptosis evasion through CCDC6 degradation
The CRC Digest